The ongoing review of the EU Pharmaceutical Legislation is looking at recalibrating IP incentives. Intellectual Property fuels medical innovations from the research bench to the patient’s bedside.
Depression impacts many more Europeans than the 40 million who suffer from it directly: it also impacts their families, their communities and their health care systems. How are Europe’s governments rising to the challenge?
Europe has led the way in developing the science of gene therapy. Now the continent needs to bring flexibility into its health systems to move from lab to reality.